Tumor risk in disorders of sex development
- PMID: 20558977
- DOI: 10.1159/000314536
Tumor risk in disorders of sex development
Abstract
Certain patients with disorders of sex development (DSD), who bear Y chromosome material in their karyotype, are at increased risk for the development of type II germ cell tumors (GCT), which arise from early fetal germ cells. DSD gonads frequently harbor immature germ cells which express early fetal germ cell markers. Some of them (e.g. OCT3/4 and NANOG) seem to be of pathogenetic relevance in GCT development providing cells with the ability of pluripotency, proliferation and apoptosis suppression. Also TSPY (testis-specific protein Y-encoded), the main candidate for the so-called gonadoblastoma locus on Y chromosome, is overexpressed in germ cells of DSD patients and possibly contributes to their survival and proliferation. Nowadays, the use of immunohistochemical methods is highly relevant in identifying DSD gonads at risk. The risk for GCT development varies. While the prevalence of GCT is 15% in patients with partial androgen insensitivity, it may reach more than 30% in patients with gonadal dysgenesis. Patients with complete androgen insensitivity and ovotesticular DSD develop malignancies in 0.8% and 2.6% of cases, respectively. However, these data may be biased for various reasons. To better estimate the risk in individual groups of DSD, further investigations on large patient series are needed.
Similar articles
-
New insights into type II germ cell tumor pathogenesis based on studies of patients with various forms of disorders of sex development (DSD).Mol Cell Endocrinol. 2008 Sep 10;291(1-2):1-10. doi: 10.1016/j.mce.2008.02.028. Epub 2008 Mar 4. Mol Cell Endocrinol. 2008. PMID: 18403106 Review.
-
Gonadoblastoma Y locus genes expressed in germ cells of individuals with dysgenetic gonads and a Y chromosome in their karyotypes include DDX3Y and TSPY.Hum Reprod. 2019 Apr 1;34(4):770-779. doi: 10.1093/humrep/dez004. Hum Reprod. 2019. PMID: 30753444
-
Tumor risk in disorders of sex development (DSD).Best Pract Res Clin Endocrinol Metab. 2007 Sep;21(3):480-95. doi: 10.1016/j.beem.2007.05.001. Best Pract Res Clin Endocrinol Metab. 2007. PMID: 17875493 Review.
-
Identification of germ cells at risk for neoplastic transformation in gonadoblastoma: an immunohistochemical study for OCT3/4 and TSPY.Hum Pathol. 2005 May;36(5):512-21. doi: 10.1016/j.humpath.2005.02.016. Hum Pathol. 2005. PMID: 15948118
-
Gonadal tumours and DSD.Best Pract Res Clin Endocrinol Metab. 2010 Apr;24(2):291-310. doi: 10.1016/j.beem.2009.10.002. Best Pract Res Clin Endocrinol Metab. 2010. PMID: 20541153 Review.
Cited by
-
Association of immunohistochemical markers with premalignancy in Gonadal Dysgenesis.Int J Pediatr Endocrinol. 2015;2015(1):14. doi: 10.1186/s13633-015-0010-6. Epub 2015 Jun 15. Int J Pediatr Endocrinol. 2015. PMID: 26089923 Free PMC article.
-
Comment on "complete androgen insensitivity syndrome: optimizing diagnosis and management".Case Rep Obstet Gynecol. 2014;2014:285715. doi: 10.1155/2014/285715. Epub 2014 May 12. Case Rep Obstet Gynecol. 2014. PMID: 24949207 Free PMC article. No abstract available.
-
A Case Report of a Rare 46,XX/47,XXY Mosaicism With Ovotesticular Disorder of Sex Development and a Literature Review.Cureus. 2024 Jul 31;16(7):e65856. doi: 10.7759/cureus.65856. eCollection 2024 Jul. Cureus. 2024. PMID: 39219924 Free PMC article.
-
Rare Disorder of Sexual Differentiation with a Mosaic 46,XX/47,XXY in a Klinefelter Syndrome Individual.J Reprod Infertil. 2020 Jul-Sep;21(3):222-224. J Reprod Infertil. 2020. PMID: 32685420 Free PMC article.
-
Early development of a gonadal tumor in a patient with mixed gonadal dysgenesis.Arch Endocrinol Metab. 2018;62(6):644-647. doi: 10.20945/2359-3997000000091. Arch Endocrinol Metab. 2018. PMID: 30624506 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials